Abstract
Dyslipidemia plays an important role in the initiation and progression of atherosclerotic coronary artery disease. However, regression of atherosclerotic atheroma by introducing lipid lowering agents is not fully understood but looks promising. More questions still need to be answered in terms of the modality of assessment, time course of changes and its documentation, whether plaque progression or regression assessed by imaging one arterial tree reflects a uniform effect throughout all arterial territories and whether atheroma regression is a therapeutic goal. Physicians need to define the type of statins, the use of statin as monotherapy or in combination with other agents, and the intensity of statin therapy. Furthermore, the impact of factors like age, gender and ethnicity on the regression process should be of consideration. We still need more randomized controlled studies based on evidence-based diagnostic interventional tools. This narrative review considers this debate.
Keywords: Atheroma, coronary artery disease, atherosclerosis, lipids, statins, regression.
Current Vascular Pharmacology
Title: Dyslipidemia, Vascular Atheroma and Statins
Volume: 13 Issue: 6
Author(s): Ahmed Abuzaid and Ayman El-Menyar
Affiliation:
Keywords: Atheroma, coronary artery disease, atherosclerosis, lipids, statins, regression.
Abstract: Dyslipidemia plays an important role in the initiation and progression of atherosclerotic coronary artery disease. However, regression of atherosclerotic atheroma by introducing lipid lowering agents is not fully understood but looks promising. More questions still need to be answered in terms of the modality of assessment, time course of changes and its documentation, whether plaque progression or regression assessed by imaging one arterial tree reflects a uniform effect throughout all arterial territories and whether atheroma regression is a therapeutic goal. Physicians need to define the type of statins, the use of statin as monotherapy or in combination with other agents, and the intensity of statin therapy. Furthermore, the impact of factors like age, gender and ethnicity on the regression process should be of consideration. We still need more randomized controlled studies based on evidence-based diagnostic interventional tools. This narrative review considers this debate.
Export Options
About this article
Cite this article as:
Abuzaid Ahmed and El-Menyar Ayman, Dyslipidemia, Vascular Atheroma and Statins, Current Vascular Pharmacology 2015; 13 (6) . https://dx.doi.org/10.2174/1570161112666141029224451
DOI https://dx.doi.org/10.2174/1570161112666141029224451 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Renal and Urological Diseases of the Newborn Neonatal Acute Kidney Injury
Current Pediatric Reviews Biocatalysis in the Pharmaceutical Industry. A Greener Future
Current Green Chemistry In Silico hERG Modeling: Challenges and Progress
Current Computer-Aided Drug Design Insulin Resistance and Postprandial Hyperglycemia the Bad Companions in Natural History of Diabetes: Effects on Health of Vascular Tree
Current Diabetes Reviews Editorial [Hot Topic:Role of Food and Nutritional Factors in Metabolic Syndrome X,Cancer and Cardiovascular Diseases (Guest Editor: Undurti N. Das)]
Current Nutrition & Food Science Editorial [Hot Topic: Analgesic Drug Discovery: Promising Future (Guest Editor: Anindya Bhattacharya)]
Current Pharmaceutical Biotechnology Medicinal Plants Targeting Cardiovascular Diseases in View of Avicenna
Current Pharmaceutical Design Combination Therapy of Statins with Ezetimibe
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Disease Modifying Osteoarthritis Drugs: Facing Development Challenges and Choosing Molecular Targets
Current Drug Targets Systemic Lupus Erythematosus: Correlation Between Immunodysregulation and Clinical Manifestations
Current Rheumatology Reviews Analytical Procedures for Secondary Metabolites Determination: Recent Trends and Future Perspectives
Letters in Drug Design & Discovery Clinical Efficacy and Effectiveness of Ursodeoxycholic Acid in Cholestatic Liver Diseases
Current Clinical Pharmacology Insulin Resistance in Nonalcoholic Fatty Liver Disease
Current Pharmaceutical Design Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry Effects of Immunosenescence on the Lower Expression of Surface Molecules in Neutrophils and Lymphocytes
Current Aging Science Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology Status of Cytokines in Ischemia Reperfusion Induced Heart Injury
Cardiovascular & Hematological Disorders-Drug Targets Dyslipidemia Treatment and Cardiovascular Disease in the Renal Patient
Current Pharmaceutical Design Possible Direct Influence of Complement 3 in Decreasing Insulin Sensitvity in a Cohort of Overweight and Obese Subjects
Endocrine, Metabolic & Immune Disorders - Drug Targets Cardiac Involvement in ANCA (+) and ANCA (-) Churg-Strauss Syndrome Evaluated by Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued)